Live Breaking News & Updates on Including Engineered Antibodies

Stay updated with breaking news from Including engineered antibodies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SystImmune to Present Data from Seven Preclinical Programs at the American Association of Cancer Research (AACR) Annual Meeting 2023

/PRNewswire/ SystImmune, Inc ("SystImmune"), a clinical-stage biopharmaceutical company specializing in the development of innovative cancer treatments. ....

United States , Jahans Khalili , Martin Olivo , Yi Zhu , Securities Exchange , Rd Center , American Association Of Cancer Research , Systimmune Inc , While Systimmune Inc , American Society Of Clinical Oncology , American Society , Clinical Oncology , American Association , Cancer Research , Including Engineered Antibodies , Factor Receptors , Therapeutic Targets , Tetra Specifict Cell , Specificity Enhanced Bi Specific Antibody , Drug Conjugate , Bai Li Pharmaceutical , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Investigational New Drug , Systimmune Inc ,

Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeu

- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener. ....

United States , David Caouette , Roger Dansey , Disitamab Vedotin , Clinical Research Excluding Trials Preclinical Therapies , Discovery Research , Children Oncology Group , Seagen Inc , Exchange Commission , American Association For Cancer Research , European Union , Clinical Research Excluding Trials Combination Immunotherapies , Initial Phase , American Association , Cancer Research , Annual Meeting , Chief Medical Officer , Seagen Presentations , Research Excluding Trials , Oncology Group , Preclinical Therapies , Clinical Observations , Pediatric Oncology , Breaking Research , Molecular Therapeutics , Pharmacologic Approaches ,

HUMMINGBIRD BIOSCIENCE PRESENTS PRE-CLINICAL DATA ON ITS NEXT-GENERATION BCMA-TACI DUAL-SPECIFIC T CELL ENGAGER AT 2021 AACR ANNUAL MEETING

Search jobs
15-Apr-2021
HUMMINGBIRD BIOSCIENCE PRESENTS PRE-CLINICAL DATA ON ITS NEXT-GENERATION BCMA-TACI DUAL-SPECIFIC T CELL ENGAGER AT 2021 AACR ANNUAL MEETING
HUMMINGBIRD BIOSCIENCE
2021 AACR ANNUAL MEETING

Singapore, April 10, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April.
HMBD-009 is Hummingbird’s next-generation T cell program that uniquely targets both B cell maturation antigen (BCMA) and Transmembrane activator and CAML Interactor (TACI), proteins commonly overexpressed in multiple myeloma, the second most common hematologic malign ....

United States , Jerome Boyd Kirkup , Clinical Research Excluding Trials , American Association For Cancer Research , Hummingbird Bioscience , Cancer Research , Annual Meeting , Rational Antibody Discovery , Chief Scientific Officer , Including Engineered Antibodies , ஒன்றுபட்டது மாநிலங்களில் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , ஹம்மிங் பறவை உயிர் அறிவியல் , புற்றுநோய் ஆராய்ச்சி , ஆண்டு சந்தித்தல் , ர்யாஶநல் ஆன்டிபாடி கண்டுபிடிப்பு , தலைமை அறிவியல் அதிகாரி , உட்பட பொறியியலாளர் ஆன்டிபாடிகள் ,

Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021

Posted on
244
Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.
“At AACR 2021, we look forward to sharing clinical and pre-clinical data from INCB106385, our novel A2A/A2B adenosine receptor antagonist, and INCA00186, our novel CD73 monoclonal antibody both of which highlight our ongoing efforts targeting the adenosine pathway. Presentations at the congress will also feature updated data from our LIMBER development program, including results from our Phase 2 combination study of ruxolitinib, a janus kinase (JAK1/JAK2) inhibitor, and parsaclisib, a potent, highly selective oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ),” said Steven Stein, M.D., Chief Medical Officer, Incyte, adding, “We f ....

United States , Catalina Loveman , Steven Stein , Exchange Commission , American Association For Cancer Research , American Association , Cancer Research , Annual Meeting , Chief Medical Officer , Suboptimal Response , Possible Therapeutic Option , Epigenetic Targets , Using Liquid Biopsy Assay , Liquid Biopsies , Preclinical Characterization , Adenosine Receptor Antagonist , Immune Checkpoints , Humanized Monoclonal Antibody Antagonist , Therapeutic Antibodies , Including Engineered Antibodies , ஒன்றுபட்டது மாநிலங்களில் , கேடலினா லவ்மேன் , ஸ்டீவன் ஸ்டீன் , பரிமாற்றம் தரகு , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , அமெரிக்கன் சங்கம் ,

LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinic

Search jobs
10-Mar-2021
LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting
UTRECHT, The Netherlands & PHILADELPHIA (BUSINESS WIRE) LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster featuring lead clinical candidate LAVA-051 will be presented at week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting, which will be held April 10-15, 2021.
The following abstract is now available on the AACR website at www.aacr.org. ....

United States , American Association For Cancer Research , American Association , Cancer Research , Annual Meeting , E Poster Session , Therapeutic Antibodies , Including Engineered Antibodies , ஒன்றுபட்டது மாநிலங்களில் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , ஆண்டு சந்தித்தல் , ஏ போஸ்டர் அமர்வு , சிகிச்சை ஆன்டிபாடிகள் , உட்பட பொறியியலாளர் ஆன்டிபாடிகள் ,